-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Rejects Capricor’s Deramiocel Application, Citing Insufficient Evidence of Effectiveness

PUBT·11/21/2026 00:57:03
FDA Rejects Capricor’s Deramiocel Application, Citing Insufficient Evidence of Effectiveness
  • Capricor Therapeutics received an FDA complete response letter for its resubmitted Deramiocel biologics license application for Duchenne muscular dystrophy.
  • The FDA found insufficient data to establish substantial evidence of effectiveness, citing other clinical deficiencies.
  • Management is reviewing the letter before determining next steps; it maintains that the clinical data support approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611201955PRIMZONEFULLFEED9882621) on November 21, 2026, and is solely responsible for the information contained therein.